Document ID: chunk:federal_register_of_legislation:F2019L01097:reg:9:p3
Version: federal_register_of_legislation:F2019L01097
Segment Type: reg
Provision Reference: reg 9 (pt 3/3)
Character Range: 9370–10275

the bladder;
Note: neurogenic bladder is defined in the Schedule 1 – Dictionary.
(15)      ingesting aristolochic acid as specified at least four years before the clinical onset of malignant neoplasm of the bladder;
Note: ingesting aristolochic acid as specified is defined in the Schedule 1 – Dictionary.
(16)      consuming a total of at least 250 grams of phenacetin at least five years before the clinical onset of malignant neoplasm of the bladder;
Note: phenacetin is defined in the Schedule 1 – Dictionary.
(17)      being treated with systemic cyclophosphamide or systemic ifosfamide, at least five years before the clinical onset of malignant neoplasm of the bladder;
(18)      being treated with chlornaphazine at least five years before the clinical onset of malignant neoplasm of the bladder;
(19)      inability to obtain appropriate clinical management for malignant neoplasm of the bladder.